Overview

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Glucagon
Glucagon-Like Peptide 1
Insulin
Insulin, Globin Zinc